- Home
- BPTH vs SYTA Comparison
BPTH vs SYTA Comparison
Compare BPTH & SYTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BPTH
- SYTA
- Stock Information
- Founded
- BPTH 2007
- SYTA N/A
- Country
- BPTH United States
- SYTA Canada
- Employees
- BPTH N/A
- SYTA N/A
- Industry
- BPTH Biotechnology: Pharmaceutical Preparations
- SYTA Telecommunications Equipment
- Sector
- BPTH Health Care
- SYTA Telecommunications
- Exchange
- BPTH Nasdaq
- SYTA Nasdaq
- Market Cap
- BPTH 5.0M
- SYTA 2.8M
- IPO Year
- BPTH N/A
- SYTA 2020
- Fundamental
- Price
- BPTH $1.09
- SYTA $6.88
- Analyst Decision
- BPTH Strong Buy
- SYTA
- Analyst Count
- BPTH 2
- SYTA 0
- Target Price
- BPTH $30.00
- SYTA N/A
- AVG Volume (30 Days)
- BPTH 6.2M
- SYTA 316.7K
- Earning Date
- BPTH 11-15-2024
- SYTA 11-14-2024
- Dividend Yield
- BPTH N/A
- SYTA N/A
- EPS Growth
- BPTH N/A
- SYTA N/A
- EPS
- BPTH N/A
- SYTA N/A
- Revenue
- BPTH N/A
- SYTA $11,988,979.00
- Revenue This Year
- BPTH N/A
- SYTA $75.92
- Revenue Next Year
- BPTH N/A
- SYTA $19.72
- P/E Ratio
- BPTH N/A
- SYTA N/A
- Revenue Growth
- BPTH N/A
- SYTA 41.59
- 52 Week Low
- BPTH $0.59
- SYTA $4.50
- 52 Week High
- BPTH $12.00
- SYTA $885.60
- Technical
- Relative Strength Index (RSI)
- BPTH 54.13
- SYTA 46.45
- Support Level
- BPTH $1.11
- SYTA $5.69
- Resistance Level
- BPTH $1.34
- SYTA $7.07
- Average True Range (ATR)
- BPTH 0.30
- SYTA 1.12
- MACD
- BPTH 0.02
- SYTA 0.15
- Stochastic Oscillator
- BPTH 16.36
- SYTA 59.50
About BPTH Bio-Path Holdings Inc.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
About SYTA Siyata Mobile Inc.
Siyata Mobile Inc is engaged in the sale of vehicle mounted, cellular-based communications platforms over advanced 3G (Third generation) mobile networks and cellular booster systems. The Company develops, markets and sells a portfolio of rugged handheld Push-to-Talk over Cellular (PoC) smartphone devices. These rugged business-to-business (B2B) environments are focused on enterprise customers, first responders, construction workers, security guards, government agencies, utilities, transportation and waste management, amusement parks, and mobile workers in multiple industries. The company operates in USA, Canada, EMEA and Australia. It derives maximum revenue from USA.